Cellectis S.A.CLLSEarnings & Financial Report
Nasdaq · research and development in biotechnology
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
NextMar 30, 2026
CLLS Q2 2025 Key Financial Metrics
Revenue
$16.7M
Gross Profit
N/A
Operating Profit
$-9.6M
Net Profit
$-23.7M
Gross Margin
N/A
Operating Margin
-57.3%
Net Margin
-141.9%
YoY Growth
107.5%
EPS
$-0.24
Financial Flow
Cellectis S.A. Q2 2025 Financial Summary
Cellectis S.A. reported revenue of $16.7M for Q2 2025, with a net profit of $-23.7M (-141.9% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $16.7M |
|---|---|
| Net Profit | $-23.7M |
| Gross Margin | N/A |
| Operating Margin | -57.3% |
| Report Period | Q2 2025 |
Income Statement
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|---|
| Revenue | $1.3M | $178000 | $8.1M | $16.7M |
| YoY Growth | -87.9% | -86.8% | 4428.7% | 107.5% |
Balance Sheet
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|---|
| Assets | $320.9M | $227.7M | $407.1M | $354.0M |
| Liabilities | N/A | N/A | $258.5M | $256.9M |
| Equity | $180.5M | $96.6M | $148.6M | $97.1M |
Cash Flow
No data available for this period
